Professional technology integration to support the entire R&D process

ADC assay validation is a formal process to demonstrate the reliability, accuracy, specificity, and robustness of a series of analytical methods used to assess key properties of ADCs, such as binding, internalization, in vitro killing, and linker stability. Given the complexity of ADC structures and the multi-step nature of their mechanisms of action (target binding-internalization-load release), validation requires an integrated strategy to systematically validate assays reflecting different functional dimensions. This document strictly adheres to the framework of the Pharmacopoeia of the People's Republic of China (ChP), particularly General Chapter 9401 "Guiding Principles for Validation of Methods for Assay of In Vitro Bioactivity/Potency of Biological Products" and related biotechnology product quality control requirements, providing a comprehensive strategy and plan for ADC bioactivity assay validation. The core of validation is to demonstrate that these methods can be used to determine the bioactivity of the test sample relative to a calibrated ADC reference standard.

The validation of ADC assays must reflect their multifunctional characteristics and follow the core strategies derived from the pharmacopoeia:

1. Functional Dimension Decomposition Validation: Decompose the biological activity of the ADC into independently verifiable dimensions, typically including antigen-binding activity, cell-killing efficacy (potency), and selective internalization efficiency assessment. Each dimension can be considered an independent "biological activity assay" for validation.

2. Reference Standard Centralization and Relative Potency: Validation and subsequent assays for each functional dimension must use the corresponding collaboratively calibrated ADC reference standard. Assay results are expressed as "relative potency" or "relative activity" relative to the reference standard.

3. System Suitability Control: Each experiment must include a reference standard and a set of mechanism controls (e.g., antigen-negative cells, isotype control ADC). Data from the run are only valid if the activity of the reference standard is within the preset range and the control results meet expectations.

4. Targeted Validation Matrix: Based on the purpose of each functional assay, selectively and intensively validate specificity, precision, accuracy, linearity and range, and robustness. Among these, cytotoxic efficacy assays typically require the most comprehensive validation.

1. Specificity

Pharmacopoeia Requirements: Demonstrate that changes in the assay signal originate from the expected biological effect produced by the ADC through its specific mechanism (antigen binding, internalization, load release).

ADC Validation Practice (Stratified Validation):

Binding Activity Assay: Using antigen-negative cells or excess soluble antigen in competition, the ADC binding signal should be significantly inhibited. Using an unrelated isotype antibody as a control, there should be no significant binding.

Cytotoxic Efficacy Assay:

Target-Dependent Validation: When tested on antigen-negative cell lines, the ADC's cytotoxic activity (EC₅₀ and maximum killing) should be significantly lower than its activity on antigen-positive cells (typically requiring a difference of more than 10-fold or meeting predetermined criteria).

Mechanism-Specific Validation: Co-treatment with a lysosomal function inhibitor (such as bafloxacin A1) should significantly attenuate the ADC's cytotoxic activity, demonstrating its dependence on lysosomal degradation.

Reference Standard Validation: Parallel testing of naked antibody and free payload is required. On antigen-positive cells, the ADC should show significantly stronger cytotoxicity than the naked antibody, and its EC₅₀ should generally be much lower than that of the free payload (when the payload concentration is adjusted for DAR).

2. Precision

Pharmacopoeia requirements include repeatability and intermediate precision.

ADC Validation Practice:

Repeatability: Perform at least six independent assays within the same plate/run for the same ADC sample (typically set near EC₅₀ concentration) to measure responses (e.g., binding MFI, cell viability inhibition rate). Calculate the coefficient of variation (CV). For titer assays, the CV for inhibition rate is typically required to be ≤ 20%; for binding assays, the CV for MFI may be more stringent (e.g., ≤ 15%).

Intermediate Precision: This is critical. The impact of different dates, operators, cell banks of different passages, and batches of key reagents (e.g., antibody detection reagents, cell viability reagents) on the results must be evaluated. The total geometrical coefficient of variation (GCV) for the relative potency or EC₅₀ of the reference sample must be reported, and acceptable standards must be set.

3. Relative Accuracy

Pharmacopoeia Requirement: The degree of agreement between the assay result and the reference value.

ADC Validation Practice: Typically assessed through a "potency recovery" experiment. Assay the ADC reference sample at at least three independent potency levels (e.g., 50%, 100%, 150% of the labeled potency).

Assess its biological activity using the method to be validated and calculate the relative potency at each level (assessed potency/labeled potency).

Calculate the geometric mean of the relative potency at all levels and its 90% or 95% confidence interval. This interval should fall entirely within the pre-defined acceptable range (e.g., 80%–125%).

4. Linearity and Range

Pharmacopoeia Requirement: The ability of the assay result to be proportional to the sample concentration within a given range.

ADC Validation Practice: Perform a series of dilutions of the ADC reference sample covering the concentration range from inactive to maximum activity.

Plot the data with the logarithm of the ADC concentration on the X-axis and the response values ​​(e.g., binding signal, inhibition rate) on the Y-axis. The data should fit well with an appropriate model (e.g., a four- or five-parameter logistic equation).

The validated linear range typically refers to the interval where the inhibition rate shows a good linear relationship with the logarithmic concentration (e.g., inhibition rate 20% to 80%). This range should be sufficient to cover the expected potency of the test sample.

5. Robustness

Pharmacopoeia requirement: The ability of the test results to remain unaffected by small, deliberate changes in assay conditions.

ADC validation practices: Vary key parameters for different types of assays:

Binding/internalization assays: Incubation temperature (±1°C), number of washes (±1), antibody incubation time (±10%).

Cell killing assays: Cell seeding density (±15%), ADC exposure time (±2 hours), final DMSO concentration (variable within a safe range).

Assess the impact of these variations on key output parameters (e.g., EC₅₀, relative potency). Variations should not cause results to exceed the reasonable range of variation derived from intermediate precision data.

Validation must begin with a detailed, pre-approved validation protocol that clearly defines:

1. Individual analysis and target overview for each functional assay (e.g., binding, killing).

2. Complete description of reference and control samples (including antigen-negative/positive cells, isotype control ADCs, and tool inhibitors).

3. Specific experimental design, acceptance criteria, and statistical analysis methods for each validation item.

Upon completion of validation, a formal validation report should be issued. The conclusion section must clearly state:

1. Whether each assay method has passed validation and its confirmed scope of application (e.g., "This cell killing assay is applicable to determining the in vitro titer of ADC candidate molecules relative to reference samples, supporting candidate molecule screening and ranking").

2. Known limitations of the method. 

3. Revalidation triggering conditions (e.g., changes to the ADC core structure (connector-loador), cell line replacement, changes to the core detection technology platform).

ADC assay validation is a multi-dimensional and rigorous evidence generation process. Based on the guidelines of the Chinese Pharmacopoeia, the scientific validity and reliability of relevant analytical methods can be systematically demonstrated through separate verification and integrated evaluation of key biological activities such as binding, internalization, and killing. A successfully validated multifunctional assay system for ADCs is not only the scientific cornerstone supporting non-clinical and clinical research, process development, and quality control of ADC drugs, but also a crucial link in ensuring the safety, efficacy, and quality control of such complex therapeutic products. All validation activities, data, and conclusions must be recorded in detail and traceably to ensure compliance with Chinese drug research and registration regulations and scientific standards.